BIOMAT Database Logo BIOMAT Database Logo

Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy. 1993

L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Department of Pediatrics, University of California, San Francisco.

OBJECTIVE To test the hypothesis that serum levels of soluble markers in children change after initiation of zidovudine therapy and that the extent and pattern of these longitudinal changes correlates with clinical outcome. METHODS We measured serum levels of soluble CD8, neopterin, beta 2-microglobulin (beta 2M), and p24 antigen, and CD4 cell counts, before the initiation of zidovudine therapy and at 12, 24 and 48 weeks of treatment in 24 HIV-1-infected children (Centers for Disease Control classification P2) and 15 controls. RESULTS Soluble CD8 levels were elevated before therapy in 70% of the infected children; subsequent decreases were associated with lower risk of disease progression. The mean serum neopterin level before treatment was elevated in infected children; decreases in neopterin levels marginally reflected improved or stable clinical status. Serum beta 2M levels and CD4+ cell counts were not associated with clinical outcome. Only 10 out of the 24 patients had detectable levels of serum p24 antigen before treatment; again, the amount of decline after initiation of therapy did not predict clinical outcome. CONCLUSIONS Decreasing levels of soluble CD8 and neopterin in HIV-1-infected children receiving zidovudine therapy might reflect a good response to treatment and a slowing of disease progression.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency

Related Publications

L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
January 1991, Journal of clinical laboratory analysis,
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
January 1990, International journal of immunopharmacology,
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Serum beta 2-microglobulin levels and p24 antigen, lymphocyte depletion and disease progression in human immunodeficiency virus infection.
January 1992, International journal of clinical & laboratory research,
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Neopterin and beta 2-microglobulin as markers for AIDS.
January 1987, Lancet (London, England),
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression.
January 1997, Journal of clinical immunology,
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Elevated pretreatment levels of soluble CD8 and Beta-2-microglobulin as indicators of relapse in breast-cancer patients.
February 1994, International journal of oncology,
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.
September 1990, AIDS (London, England),
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.
January 1992, Journal of acquired immune deficiency syndromes,
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Evaluation of serum levels of soluble CD4, CD8 and beta 2-microglobulin in visceral human leishmaniasis.
August 1994, Clinical and experimental immunology,
L Siller, and N L Martin, and P Kostuchenko, and L Beckett, and J Rautonen, and S C Cheng, and D W Wara
Serum neopterin, beta2-microglobulin, soluble interleukin-2 receptors, and immunoglobulin levels in healthy adolescents.
August 1998, Clinical immunology and immunopathology,
Copied contents to your clipboard!